New Methods of Endocrine Management of Prostatic Cancer

January 1987 in “ The Journal of urology/The journal of urology ”

Joseph A. Smith

nonsteroidal antiandrogens luteinizing hormone-releasing hormone agonists androgen withdrawal therapies testicular impairment LHRH agonists

TLDR New hormonal therapies can help treat advanced prostate cancer but may cause testicular issues.

The document reviewed new methods of endocrine management for prostatic cancer as of 1987. It discussed various hormonal therapies and their effectiveness in treating advanced stages of the disease. The review highlighted the use of nonsteroidal antiandrogens, luteinizing hormone-releasing hormone (LHRH) agonists, and other androgen withdrawal therapies. The findings suggested that these treatments could induce regression in prostate cancer, although long-term use might lead to testicular impairment. The review provided a comprehensive overview of the available endocrine treatment options and their potential impacts on patients.

View this study on auajournals.org →

Discuss this study in the Community →

Related Community Posts Join

6 / 52 results

community [Research] RU-58841/Pyrilutamide and impacts on male fertility

in Research/Science 6 upvotes 1 year ago

The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.

community DHT blocking ingredients

in Treatment 6 upvotes 3 years ago

The conversation discusses DHT blocking treatments for hair loss, specifically mentioning Minoxidil, Finasteride, and organic flaxseed oil containing omega-3 fatty acids. It highlights skepticism about alternative treatments and emphasizes the proven effectiveness of Finasteride and Dutasteride.

community Binding affinity of pyrilutamide!

in Update 170 upvotes 2 years ago

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

community Fluridil downregulates androgen receptor expression?

in Research/Science 1 upvotes 1 year ago

Fluridil may decrease the number of androgen receptors in hair follicles by up to 95%. This suggests a different action mechanism from other non-steroidal antiandrogens like RU58841, indicating they might be used together.

community Methods Of Staying Safe On Ru58841 - My 2 Cents

in Research/Science 9 upvotes 2 weeks ago

RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.

community 2 years on dut (.5mg three times per week) 1 and a half on RU 5% (once a day)

in Progress Pictures 261 upvotes 3 weeks ago

The user experienced significant hair regrowth using dutasteride (0.5 mg three times a week) and RU58841 (5% once a day), with no side effects reported from RU58841. They are considering increasing the RU58841 dose or adding minoxidil for further improvement.

Related Research

1 / 1 results

research Finasteride

10 citations, June 2010 in “Expert Opinion on Drug Metabolism & Toxicology”

Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.